The HOPE Study and MICRO-HOPE Substudy: effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus
|
|
- Nickolas James
- 7 years ago
- Views:
Transcription
1 The HOPE Study and MICRO-HOPE Substudy: effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus VINOD PATEL, 1 SRINIVAS PANJA, 1 ASOK VENKATARAMAN 2 Background ACE inhibitors have a special role in diabetes care. They have been proven to reduce urinary albumin excretion and reduce the rate of progression of diabetic nephropathy and retinopathy. 1-3 There is proven benefit post myocardial infarction, with a greater beneficial effect in patients with diabetes in comparison to those without. 4 The effect of ACE inhibitors in patients who have low ejection fractions or overt cardiac failure is well described. More recent studies indicate other benefits of ACE inhibitors such as improving dyslipidaemia and insulin sensitivity. Cardiovascular disease is the commonest cause of mortality among patients with type 2 diabetes. A recent study reports the standardised mortality ratio to be considerably higher in people with diabetes with the vast majority of the excess due to cardiovascular disease (type 1 diabetes: women x 6.41, men x 2.94, type 2 diabetes: women x 1.6, men x 1.41). 6 Patients with type 2 diabetes who have no evidence of previous coronary heart disease were found to be at the same risk of myocardial infarction and cardiovascular death as non-diabetic patients who had already suffered from a myocardial infarction. 7 The diabetes subject cohort of the HOPE Study, (Heart Outcomes Prevention Evaluation Study), sought to investigate whether ACE inhibitor treatment with ramipril in high-risk patients with diabetes lowers the risk of cardiovascular events. 8 Within this main study the MICRO-HOPE substudy investigated the effect of ACE inhibitor treatment with ramipril on microalbuminuria and diabetic retinopathy. 9 The aim of this article is to offer a clinical summary of the above studies and suggest recommendations for clinical practice. Key words: diabetes, cardiovascular disease, microvascular complications, HOPE study, ACE inhibitor. Diabetes and Endocrinology Centre, 1 Coronary Care Unit, 2 George Eliot Hospital NHS Trust, Nuneaton, UK. Correspondence to: Dr Vinod Patel Diabetes and Endocrinology Centre, George Eliot Hospital NHS Trust, College Street, Nuneaton, Warwickshire, CV1 7DJ, UK. Tel: +44 () ; Fax: +44 () vinod.patel@geh-tr.wmids.nhs.uk Br J Diabetes Vasc Dis 21;1:44 1 Methodology Subjects: People with diabetes age or more with previous history of cardiovascular disease, (coronary artery disease, stroke, peripheral vascular disease) or one cardiovascular risk factor (total cholesterol >.2 mmol/l, HDL cholesterol.9 mmol/l, hypertension, known microalbuminuria, current smoking status). Exclusion criteria: Dipstick positive proteinuria, established diabetic nephropathy, severe renal disease, hyperkalaemia, congestive cardiac failure, low ejection fraction, (< 4%), uncontrolled hypertension, recent myocardial infarction or stroke. Sites: Study conducted in 281 centres in 19 countries in North and South America and Europe, (Argentina, Austria, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Ireland, Italy, Mexico, Netherlands, Norway, Spain, Sweden, Switzerland, UK, USA). Ethics: The HOPE Study protocol was approved locally by Ethics Committees and all subjects provided written informed consent. Study design: The study was a 2 x 2 design with randomisation of subjects to 1 mg ramipril or placebo taken once-daily in the evening and 4 IU of Vitamin E or placebo daily. Follow-up visits at one month and then every six months. Duration of study was 4. years. Treatment: The initial running period 2. mg ramipril for 7 1 days, continued into the study if creatinine concentration 2 µmols or lower and potassium <. mmol/l or lower. Primary end point: Development of myocardial infarction, stroke, cardiovascular death. Secondary end point: Total mortality admission to hospital for congestive cardiac failure, unstable angina, cardiovascular and revascularisation, overt nephropathy, heart failure, worsening angina, development of diabetes in subjects with no history of diabetes. Other points: Patients were judged to have type 2 diabetes if they developed diabetes at age 3 years or older or were not taking insulin. Hypertension was defined as taking drugs to treat hypertension or blood pressure greater than 16/9 mmhg. MICRO-HOPE Substudy: Urinary albumin excretion measured at baseline one year end of study by the albumin and creatinine ratio in a first morning sample. Microalbuminuria defined as an albumin/creatinine ratio of 2 mg/mmol or higher in men and women. Overt nephropa- 44 THE BRITISH JOURNAL OF DIABETES AND VASCULAR DISEASE
2 thy defined as 24-hour urine albumin 3 mg or greater or 24-hour urine total protein mg or greater, or albumin/creatinine ratio greater than 36 mg/mmol. Statistical analysis This study was adequately powered to detect relative risk reduction in the rate of myocardial infarction, stroke or cardiovascular disease. The study was ended six months earlier than the five years planned on the recommendation of the independent data safety and monitoring board. Intention to treat analysis. Results reported as relative risk reductions, Kaplan-Meier curves to estimate survival. ANOVA analysis adjusted for baseline values. Cox s regression model for interactions. Results There were 9,41 participants in the HOPE Study of which 3,64 had diabetes (39.3%). The results are presented on this group alone. Some patients (n=77) participated in another substudy in which they only received 2. mg of ramipril and therefore the main data set is on the 3,77 subjects receiving 1 mg ramipril. Mean age % female. 6% previous history of hypertension. At the end of study 6% in the placebo group and 66% in the ramipril group were still taking the study drugs at the end of the 4. years of the study. At four years 12% of the ramipril group and 1% of the placebo group were taking open label ACE inhibitors. Reasons for stopping ramipril were cough, dizziness, angioedema, hypertension or clinical event. The reasons for open label ACE inhibitor use in the placebo group were heart failure, proteinuria or hypertension. Primary outcomes Combined primary outcome of myocardial infarction, stroke or cardiovascular death reduced by 2%, (ramipril 1.3% versus 19.8% placebo). Myocardial infarction reduced 22%, (ramipril 1.2% versus 12.9% placebo). Stroke reduced 33%, (ramipril 4.2% versus 6.1% placebo). Cardiovascular death reduced 37%, (ramipril 6.2% versus placebo 9.7%). Secondary outcomes Total mortality reduced 24% Revascularisation reduced 17% Overt nephropathy reduced 24% Overt nephropathy, laser, therapy or dialysis reduced 16%. Other outcomes Any heart failure reduced 2%. Transient ischaemic attacks reduced 26%. Worsening angina reduced 13%, (p=.7). The benefit of ramipril was noted irrespective of whether subjects had a history of previous cardiovascular events, hypertension or microalbuminuria, or whether the patients had type 1 or 2 diabetes. At the end of the study there is no significant difference in HbA 1C % values. Blood pressure difference was 2.47/1. in favour of ramipril. After adjustment and changes in blood pressure, ramipril had the same effect on primary outcomes as before adjustment. Vitamin E had no significant effect. Treatment of 1, patients with ramipril for four years will prevent about 1 events in approximately 7 patients. 8 Clinical practice comments ACE inhibition significantly reduced the risk of major cardiovascular outcomes by 2 3% in a broad range of patients with diabetes, years of age or greater. These results would apply to the vast majority of our patients with diabetes as 7% have hypertension, another 7% have dyslipidaemia, 2% smoke and 1% have microalbuminuria. The results of the HOPE and MICRO-HOPE study therefore apply to around 8% of patients with diabetes in the study age group. Ramipril also reduced the risk of the development of overt nephropathy, renal failure or need for laser treatment. The treatment effect is comparable to other cardiovascular prevention measures such as aspirin prophylaxis, statin treatment for dyslipidaemia and treatment of hypertension. 1,11 The number needed to treat to prevent a major cardiovascular or microvascular event would be 1 high-risk patients with diabetes for 4. years to prevent one individual from having a myocardial infarction, stroke, cardiovascular death, admission to hospital for cardiac failure, revascularisation, development of overt nephropathy, laser treatment for sight threatening diabetic retinopathy or renal dialysis. This equates to a drug cost of to prevent one of the above events. It is probably fair to state that the risk reduction in cardiovascular events is greater than a blood pressure effect alone. However, this requires further close scrutiny as the ramipril group had a distinctly lower blood pressure (by 2.47/1. mmhg) with a probable greater effect on the 24- hour ambulatory blood pressure. The cardiovascular protective effects of ACE inhibitors may be due to an effect on the endothelium via angiotensin II. The latter is a powerful vasoconstrictor which promotes vascular smooth muscle proliferation by induction of protooncogenes and various growth factors. Angiotensin II stimulates the release of endothelin. It also inhibits fibrinolysis and promotes thrombosis. ACE inhibition will therefore reduce plaque rupture and cardiovascular events. Bradykinin which is increased with ACE inhibitor treatment is a vasodilator and would have the opposite effects of angiotensin II. The results of this study concord with other studies with ACE inhibitors. For example the Captopril Prevention Project which found 14% reduction in rate of myocardial infarction, stroke or cardiovascular death in patients taking VOLUME 1 ISSUE 1. AUGUST 21 4
3 Figure 1. HOPE - Primary outcomes Figure 3. HOPE - Other outcomes nnt 167/yr 22% nnt 1/yr 2% nnt 237/yr 33% nnt 128/yr 37% nnt 196/yr 13% nnt 18/yr 16% nnt 196/yr 2% nnt 3/yr 26% MI Combined CVA CV death Worsening angina Overt nephropathy Any heart failure TIA Figure 2. HOPE - Secondary outcomes Table 1. A strategy to reduce cardiovascular mortality in diabetes care 18 2 nnt 141/yr 24% nnt 237/yr 24% Primary prevention by treatment of cardiovascular risk factors nnt 188/yr 17% Revascularisation Mortality Nephropathy Exercise, healthy diet, obesity management, smoking cessation Control of hypertension (BP 14/8) Glycaemic control (HbA lc 7%) Cholesterol reduction with statins (T. chol., LDL 3., HDL.9) Secondary prevention of cardiovascular disease Aspirin 7 mg od Beta blockers ACE inhibitors Intensive insulin therapy (Digami protocol) 19 Cholesterol reduction with statins Other preventive measures Ramipril 1 od (HOPE study) Aspirin 7 mg od 2 Surgical treatment of coronary heart disease Interventional cardiology Surgical captopril. 12 However other studies have shown no distinct benefit of ACE inhibitors over beta blockers. 13 The beneficial effect of ramipril was independent of whether the subject was already taking cardiovascular disease prevention agents such as aspirin, beta blockers or lipid-lowering agents. With respect to microvascular outcomes, these results concord with the results of the Eurodiab Controlled trial of Lisinopril in insulin-dependent diabetes (EUCLID) nephropathy and the EUCLID retinopathy studies (using lisinopril 2 mg od), although these were type 1 diabetes mellitus patients only. Microvascular complications may have improved due to a beneficial effect on microvascular autoregulation. 14 The HOPE Study contained a comparable number of patients as the UKPDS in an equally well designed study. The results should therefore be taken seriously with the findings implemented in clinical practice. Ramipril now has a license for reducing the risk of myocardial infarction/cardiovascular disease or need for revascularisation procedures in diabetic patients of years or more who have one or more of the following clinical findings: Hypertension (greater than 16/9 mmhg), dyslipidaemia, cholesterol (greater than.2, HDL <.9), current smoker, known microalbuminuria, clinical evidence of previous vascular disease. Other indications for ACE inhibitors including mild to moderate hypertension, congestive cardiac failure as adjunct to diuretic therapy and reduction in mortality in patients surviving acute myocardial infarction with clinical evidence of heart failure. Lisinopril 48 THE BRITISH JOURNAL OF DIABETES AND VASCULAR DISEASE
4 Table 2. Risk reductions and NNT values for recent large trials in diabetes care 17 UKPDS- glycaemic control UKPDS metformin UKPDS-Hypertension HOPE trial 1 subtrial 16 trial 1 MICRO-HOPE End point RR nnt/yr RR nnt/yr RR nnt/yr RR nnt/yr any Diabetes end point.1% % % Death from diabetes - -.2% % Death from all causes % % 141 Myocardial infarction 2.7% 37 7% % 167 Stroke % % 237 Microvascular complications 2.8% % %* 18* * overt nephropathy, laser therapy, or dialysis; RR = risk reduction; also has a licence for prevention of nephropathy in albuminuric patients with normotensive type 1 diabetes and hypertensive type 2 diabetes. Rather than risk reductions from a health planning point of view, it is probably better to look at number needed to treat (NNT) to prevent an event. NNT is calculated as 1%/absolute % reduction in risk and denotes the number of subjects who must receive the study treatment to prevent one event. To illustrate its use, consider treatment A which reduces risk of Event X from 1% per year to % (also a risk reduction of %). The NNT is 1%/1 = 2 per year. Now consider treatment B which reduces risk of Event Y from 1% per year to.% (also a risk reduction of %). The NNT is 1%/1.. = 2 per year. Clearly the NNT is a valuable concept in considering treatment effects and calculating costs of healthcare. The risk reduction and NNTs for the main outcomes are shown in figures 1 3. NNT s are shown in graphs 1, 2 and 3 with comparisons to the main United Kingdom Prospective Diabetes Study (UKPDS) studies shown in table 1. How to use ramipril 2. mg once a day for one week, mg for three weeks and then 1 mg daily. In clinical practice ramipril is frequently given mg od for one week followed by 1 mg od. Urea, potassium and creatinine levels should be checked after 2 4 weeks on ACE inhibition with the ACE inhibitor discontinued if the urea rises by % or more or if the creatinine rises by more than 2%. Attention to other drugs which worsen renal parameters (diuretics and other vasodilators) may allow continued use of ACE inhibitors. Conclusion At the average age of diagnosis of diabetes ( years), the estimated life expectancy is reduced by seven years in women and five years in men, 8% of these premature deaths are due to cardiovascular disease. 6 All diabetes care programmes should aim to reduce cardiovascular disease by an aggressive strategy to decrease blood pressure to the target of 14/8 mmhg or lower, improve glycaemic control to a target HbA 1C of 7% or lower, lipid lowering (total cholesterol < mmol/l, LDL < 3 mmol/l, HDL >.9 mmol/l), smoking cessation, aspirin treatment, together with due attention to healthy eating, exercise and weight reduction. The HOPE and MICRO-HOPE Study clearly shows the beneficial effect of adding an ACE inhibitor into this strategy (table 2). References 1. Lewis EJ, Hunsickler LG, Bain RP, Rohde RD. The effect of angiotensinconverting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329: The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349: Chaturvedi N, Sijolie AK, Stephenson JM et al. and the EUCLID Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with Type 1 diabetes. Lancet 1998;31: GISSI-3 study group. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343: Shindler DM, Kostis JB, Yusuf S et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiology 1996;77: Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 21;7299: Haffner SM, Lehto S, Rönnemaa T et al. Kaplan-Meier estimates of the probability of death from coronary heart disease in subjects who had not had a previous myocardial infarction. N Engl J Med 1998;339: The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2;342: The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO- HOPE substudy. Lancet 2;3: Pyorali K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prog- THE BRITISH JOURNAL OF DIABETES AND VASCULAR DISEASE
5 nosis of diabetic patients with coronary heart disease. Diabetes care 1997;2: UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998;317: Hansson L, Lindholm LH, Niskanen L et al. Effect of ACE-inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;33: UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 1998;317: Patel V, Rassam SMB, Chen HC, Kohner EM. Effect of angiotensin-converting enzyme inhibition with perindopril and β-blockade with atenolol on retinal blood flow in hypertensive diabetic subjects. Metabolism 1998;47(Supp 1): UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;32: UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;32: Stratton IM, Cull CA, Manley SE et al. Relation between diabetes and hyperglycaemia and cardiovascular disease has not been resolved (authors reply). BMJ 21;322: Miles Fisher B. Results of the Heart Outcomes Prevention Evaluation (HOPE) Study: Implications for the care of people with diabetes. Modern Diabetes Management 2;1: Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997;314: Aspirin and diabetes (Fact sheet 21). Diabetes Update, Diabetes UK Summer 21. VOLUME 1 ISSUE 1. AUGUST 21 1
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationDiabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
More informationUnderstanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
More informationDrug Treatment in Type 2 Diabetes with Hypertension
Hypertension is 1.5 2 times more prevalent in Type 2 diabetes (prevalence up to 80 % in diabetic subjects). This exacerbates the risk of cardiovascular disease by ~ two-fold. Drug therapy reduces the risk
More informationIn many diabetes units, people with type
Renal Microalbuminuria: Screening and management in type 2 diabetes Julia Arundale Introduction In many diabetes units, patients with type 1 or type 2 diabetes are screened for proteinuria. Screening for
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationManaging diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
More informationCardiovascular Risk in Diabetes
Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationMicroalbuminuria: We are in the midst of an epidemic: the epidemic. So What s a Little Protein? Malcolm s diabetes. How much is too much?
Focus on CME at the University of Saskatchewan Microalbuminuria: So What s a Little Protein? By Judith T. Klassen, BSc, MD, FRCPC University of Saskatchewan Practical Management of Common Medical Problems
More informationDiabetes and the Kidneys
Diabetes and the Kidneys Aim(s) and objective(s) This guideline focuses on the detection, prevention, and management of kidney disease in people with diabetes. The management of end-stage renal disease
More informationPrescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital
Research Article Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital *T. JANAGAN 1, R. KAVITHA 1, S. A. SRIDEVI
More informationEUROASPIRE II. European Action on Secondary and Primary Prevention through Intervention to Reduce Events
II European Action on Secondary and Primary Prevention through Intervention to Reduce Events Euro Heart Survey Programme European Society of Cardiology-ESC 1 2 Priorities of Coronary Heart Disease Prevention
More informationCase Study 6: Management of Hypertension
Case Study 6: Management of Hypertension 2000 Scenario Mr Ellis is a fit 61-year-old, semi-retired market gardener. He is a moderate (10/day) smoker with minimal alcohol intake and there are no other cardiovascular
More informationGUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*
71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the
More informationRenal Disease in Type 2 Diabetes Mellitus
Renal Disease in Type 2 Diabetes Mellitus 6th Collaborative DiGP/HSE/UCC Conference 25 th September 2013 Dr. Eoin O Sullivan Consultant Endocrinologist Bon Secours Hospital Cork Case 69 year old woman
More informationPRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION
Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181
More informationDiabetic Nephropathy
Diabetic Nephropathy Kidney disease is common in people affected by diabetes mellitus Definition Urinary albumin excretion of more than 300mg in a 24 hour collection or macroalbuminuria Abnormal renal
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationHypertension Guidelines
Overview Hypertension Guidelines Aim to reduce Blood Pressure to 140/90 or less (140/80 for diabetics), adding drugs as needed until further treatment is inappropriate or declined. N.B. patients do not
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationOverview and update of modern type 2 Diabetes philosophy and management. Dr Steve Stanaway Consultant Endocrinologist BCU
Overview and update of modern type 2 Diabetes philosophy and management Dr Steve Stanaway Consultant Endocrinologist BCU Diabetes economics 2009: 2.6M adults with DM in UK (90% type 2) 2025: est. > 4M
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationDIABETES CARE. Advice. Blood Pressure. Cholesterol. Diabetes control. Eyes. Feet. Guardian Drugs
DIABETES CARE What happens if you follow the Alphabet Strategy? As patients reach their targets, the chances of developing serious complications of diabetes will be reduced! 1 Stroke Eye disease Heart
More informationROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE
ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.
More informationAppropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial
Appropriate in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial Robert W Schrier*, Raymond O Estacio, Philip S Mehler and William R Hiatt SUMMARY The hypertensive and
More informationAggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost
Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost Naftali Stern Institute of Endocrinology, Metabolism and Hypertension Tel Aviv -Sourasky Medical Center and Sackler
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationSUMMARY OF CHANGES TO QOF 2015/16 - ENGLAND CLINICAL
SUMMARY OF CHANGES TO QOF 2015/1 - ENGLAND KEY No change Retired/replaced Wording and/or change Point or threshold change Indicator ID change 14/15 QOF ID 15/1 QOF ID NICE ID Indicator wording Changes
More informationTrends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins
Type 2 Diabetes Type 2 diabetes is the most common form of diabetes, accounting for 90 95% of cases. 1 Charts 1 and 2 reflect the effect of increasing prevalence on prescribing and costs of products used
More informationHYPERTENSION ASSOCIATED WITH RENAL DISEASES
RENAL DISEASE v Patients with renal insufficiency should be encouraged to reduce dietary salt and protein intake. v Target blood pressure is less than 135-130/85 mmhg. If patients have urinary protein
More informationInsulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks
Background: Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 19, 2015 The Centers for Disease Control
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationHypertension and Diabetes
Hypertension and Diabetes C.W. Spellman, D.O., Ph.D., FACOI Professor & Associate Dean Research Dir. Center Diabetes & Metabolic Disorders Texas Tech University Health Science Center Midland-Odessa, Texas
More informationInDependent Diabetes Trust
InDependent Diabetes Trust Kidneys and Diabetes Updated July 2015 Registered Company Number 3148360 Registered Charity No 1058284 Contents Introduction Healthy Kidneys Kidney disease and diabetes The use
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationQuantifying Life expectancy in people with Type 2 diabetes
School of Public Health University of Sydney Quantifying Life expectancy in people with Type 2 diabetes Alison Hayes School of Public Health University of Sydney The evidence Life expectancy reduced by
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationScottish Diabetes Survey 2013. Scottish Diabetes Survey Monitoring Group
Scottish Diabetes Survey 2013 Scottish Diabetes Survey Monitoring Group Contents Contents... 2 Foreword... 4 Executive Summary... 6 Prevalence... 8 Undiagnosed diabetes... 18 Duration of Diabetes... 18
More informationInternational Task Force for Prevention Of Coronary Heart Disease. Clinical management of risk factors. coronary heart disease (CHD) and stroke
International Task Force for Prevention Of Coronary Heart Disease Clinical management of risk factors of coronary heart disease and stroke Economic analyses of primary prevention of coronary heart disease
More informationHow To Determine The Prevalence Of Microalbuminuria
Research Journal of Pharmaceutical, Biological and Chemical Sciences Prevalence of Microalbuminuria in relation to HbA1c among known Type2 Diabetic Patients in Puducherry population Muraliswaran P 1 *,
More informationScottish Diabetes Survey 2014. Scottish Diabetes Survey Monitoring Group
Scottish Diabetes Survey 2014 Scottish Diabetes Survey Monitoring Group Contents Table of Contents Contents... 2 Foreword... 4 Executive Summary... 6 Prevalence... 8 Undiagnosed diabetes... 21 Duration
More informationCardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011
Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process
More informationAbsolute cardiovascular disease risk assessment
Quick reference guide for health professionals Absolute cardiovascular disease risk assessment This quick reference guide is a summary of the key steps involved in assessing absolute cardiovascular risk
More information( Diabetic nephropathy) ( Microalbuminuria ) ( Macroalbuminuria )
2006 17 99-105 2006 20-40% ( ESRD ) 30 299 mg ( ) ( 300 mgday ) DCCBs ) dihydropyridine calcium channel blockers ( non- DCCBs ( -blockers ( diuretics ) 10%) 0.8 ( 60 mlmin per 1.73 m 2 30 mlmin per 1.73
More informationNew in Diabetes. Diabetes is becoming more common. By the. What s. Presented at McMaster University, Hamilton, Ontario, October 2001.
Focus on CME at McMaster University What s New in Diabetes By Sarah Capes, MD, FRCPC Presented at McMaster University, Hamilton, Ontario, October 2001. Diabetes is becoming more common. By the year 2025,
More informationCase study 28: Managing hypertension in diabetes
Case study 28: Managing hypertension in diabetes October 2003 An Independent, Australian organisation for Quality Use of Medicines National Prescribing Service Limited ACN 082 034 393 Level 7/418A Elizabeth
More informationHIGH BLOOD PRESSURE AND YOUR KIDNEYS
HIGH BLOOD PRESSURE AND YOUR KIDNEYS www.kidney.org About the Information in this Booklet Did you know that the National Kidney (NKF) Foundation offers guidelines and commentaries that help your healthcare
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationPrimary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD
Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD Date written: July 2012 Author: Kate Wiggins, Graeme Turner, David Johnson GUIDELINES We
More informationMANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
More informationPHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
More informationECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationCoronary Artery Disease leading cause of morbidity & mortality in industrialised nations.
INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.
More informationGuideline for Microalbuminuria Screening
East Lancashire Diabetes Network Guideline for Microalbuminuria Screening Produced by: Task and Finish Group, Clinical Standards Group Produced: August 2006 Approved by: East Lancashire Diabetes Network
More informationCardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationRivaroxaban for acute coronary syndromes
Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following
More informationPosition Statement Diabetic Nephropathy American Diabetes Association
Information obtained from the American Diabetes Association 2002 by the American Diabetes Association, Inc. Publication Date January 2002 in Diabetes Care 25:S85-S89, 2002 Edited by the Nephrology Department,
More informationMicroalbuminuria: An increasingly recognized risk factor for CVD
Microalbuminuria: An increasingly recognized risk factor for CVD Long known to be associated with kidney disease, the importance of protein in the urine is now becoming recognized as a sensitive, accessible
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationUse of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Number 84 Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus Summary Overview Clinical
More informationDCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study
DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study National Diabetes Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What
More informationType 1 Diabetes ( Juvenile Diabetes)
Type 1 Diabetes W ( Juvenile Diabetes) hat is Type 1 Diabetes? Type 1 diabetes, also known as juvenile-onset diabetes, is one of the three main forms of diabetes affecting millions of people worldwide.
More informationScottish Diabetes Survey
Scottish Diabetes Survey 2011 Scottish Diabetes Survey Monitoring Group Foreword The Scottish Diabetes Survey 2011 data reflects many aspects of the quality of diabetes care across the whole of Scotland.
More informationPrevention and management of chronic kidney disease in type 2 diabetes
162..194 NEPHROLOGY 2010; 15, S162 S194 doi:10.1111/j.1440-1797.2010.01240.x Prevention and management of chronic kidney disease in type 2 diabetes Date written: April 2009nep_1240 Final submission: April
More informationHypertension Guideline V4
Hypertension Guideline V4 Approved 24/06/2008 Version VERSION 4 FINAL Date of First Issue 26/02/08 Review Date 01/03/2010 Date of Issue 24/06/2008 EQIA Yes / No 24/06/2008 Author / Contact Dr Leslie Cruickshank
More informationStatin Template Guidance Use of statins in primary and secondary prevention of vascular disease Endorsed by ABHB MTC for use in Gwent (October 2012)
Statin Template Guidance Use of statins in primary and secondary prevention of vascular disease Endorsed by ABHB MTC for use in Gwent (October 2012) Notes relating to this guidance This guidance serves
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationPROCEEDINGS DIABETIC NEPHROPATHY: DETECTION AND TREATMENT OF RENAL DISEASE IN PATIENTS WITH DIABETES* Jiten Vora, MA, MD, FRCP ABSTRACT
DIABETIC NEPHROPATHY: DETECTION AND TREATMENT OF RENAL DISEASE IN PATIENTS WITH DIABETES* Jiten Vora, MA, MD, FRCP ABSTRACT Diabetic nephropathy affects people with either type 1 or type 2 diabetes mellitus.
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 25 September 2008 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
More informationHigh Blood pressure and chronic kidney disease
High Blood pressure and chronic kidney disease For People with CKD Stages 1 4 www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National Kidney
More informationDiabetes and Heart Disease
Diabetes and Heart Disease Diabetes and Heart Disease According to the American Heart Association, diabetes is one of the six major risk factors of cardiovascular disease. Affecting more than 7% of the
More informationADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE
I. PURPOSE To establish guidelines for the monitoring of antihypertensive therapy in adult patients and to define the roles and responsibilities of the collaborating clinical pharmacist and pharmacy resident.
More informationASSOCIATED FACTORS OF EJECTION FRACTION IN INSULIN-TREATED PATIENTS WITH TYPE 2 DIABETES
Rev. Med. Chir. Soc. Med. Nat., Iaşi 204 vol. 8, no. 4 INTERNAL MEDICINE - PEDIATRICS ORIGINAL PAPERS ASSOCIATED FACTORS OF EJECTION FRACTION IN INSULIN-TREATED PATIENTS WITH TYPE 2 DIABETES Gina Botnariu
More informationClinical Quality Measure Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW
Clinical Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW NQF 0105 PQRS 9 NQF 0002 PQRS 66 Antidepressant Medication Management Appropriate Testing for Children with Pharyngitis (2-18 years)
More information8-9-2012. In hospital diabetes care background and challenges. Duality of interest. One of the goals may be...
In hospital diabetes care background and challenges Duality of interest Nothing to disclose within the framework of this presentation My own fasting BG is 4.6 mmol/l, HbA1c 5.4% Bruce H.R. Wolffenbuttel
More informationMar. 31, 2011 (202) 690-6145. Improving Quality of Care for Medicare Patients: Accountable Care Organizations
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services Room 352-G 200 Independence Avenue, SW Washington, DC 20201 Office of Media Affairs MEDICARE FACT SHEET FOR IMMEDIATE RELEASE
More informationDavid Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
More informationAfter acute myocardial infarction, diabetes CARDIAC OUTCOMES AFTER MYOCARDIAL INFARCTION IN ELDERLY PATIENTS WITH DIABETES MELLITUS
CARDIAC OUTCOMES AFTER MYOCARDIAL INFARCTION IN ELDERLY PATIENTS WITH DIABETES MELLITUS By Deborah Chyun, RN, PhD, Viola Vaccarino, MD, PhD, Jaime Murillo, MD, Lawrence H. Young, MD, and Harlan M. Krumholz,
More informationDrug treatment of elevated blood pressure
Drug treatment of elevated blood pressure Mark Nelson, Professor and Chair, Discipline of General Practice Professorial Research Fellow, and Senior Member, Menzies Research Institute, University of Tasmania,
More informationFewer people with coronary heart disease are being diagnosed as compared to the expected figures.
JSNA Coronary heart disease 1) Key points 2) Introduction 3) National picture 4) Local picture of CHD prevalence 5) Mortality from coronary heart disease in Suffolk County 6) Trends in mortality rates
More information2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk Lynne T Braun, PhD, CNP, FAHA, FAAN Professor of Nursing, Nurse Practitioner Rush University Medical Center 2
More informationJill Malcolm, Karen Moir
Evaluation of Fife- DICE: Type 2 diabetes insulin conversion Article points 1. Fife-DICE is an insulin conversion group education programme. 2. People with greater than 7.5% on maximum oral therapy are
More informationThe Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery
The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery Michael E. Farkouh, MD, MSc Peter Munk Chair in Multinational Clinical Trials Director, Heart and Stroke
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationMultiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden
Multiple comorbidities: additive and predictive of cardiovascular risk Peter M. Nilsson Lund University University Hospital Malmö, Sweden Clinical outcomes: major complications of CVD Heart Attack/ACS
More informationHigh Blood Pressure and Your Kidneys
High Blood Pressure and Your Kidneys About 65 million Americans have high blood pressure, but as many as one third or three in 10 don't even know it. There are usually no signs or symptoms that your blood
More informationPrevention of stroke in patients with atrial fibrillation
www.sign.ac.uk Prevention of stroke in patients with atrial fibrillation A guide for primary care January 2014 Evidence Contents 1 Introduction... 1 2 Detection...2 3 Risk stratification... 3 4 Treatment
More informationPsoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis
Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic
More informationMEDICATION THERAPY ADHERENCE CLINIC : DIABETES
MEDICATION THERAPY ADHERENCE CLINIC : DIABETES PHARMACEUTICAL SERVICES DIVISION MINISTRY OF HEALTH MALAYSIA First Edition, 2010 Pharmaceutical Services Division Ministry of Health, Malaysia ALL RIGHT RESERVED
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationHigh Blood Pressure (Essential Hypertension)
Sacramento Heart & Vascular Medical Associates February 18, 2012 500 University Ave. Sacramento, CA 95825 Page 1 916-830-2000 Fax: 916-830-2001 What is essential hypertension? Blood pressure is the force
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationClinical Study The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular Disease A Retrospective Single Center Experience
International Scholarly Research Network ISRN Cardiology Volume 2012, Article ID 874706, 5 pages doi:10.5402/2012/874706 Clinical Study The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular
More information